OncoMatch/Clinical Trials/NCT06840119

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Is NCT06840119 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for cancer.

Phase 1/2RecruitingImmunocore LtdNCT06840119Data as of Jun 2026Location: International · 6 countries

Treatment: IMC-R117C · Chemotherapy drug · Chemotherapy drug · Kinase inhibitor · Antiangiogenic Agent · Monoclonal antibody — This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

IMC-R117CChemotherapy drugChemotherapy drugKinase inhibitorAntiangiogenic AgentMonoclonal antibody

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: applicable standard treatments

Previously received applicable standard treatments

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06840119 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received applicable standard treatments.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify